These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 31350777)

  • 21. Paradoxical Psoriasiform Eruptions in Children Receiving Tumor Necrosis Factor α Inhibitors.
    Eickstaedt J; Paller AS; Lund E; Murphrey M; Brandling-Bennett H; Maurano M; Fernandez Faith E; Holland KE; Ibler E; Liang MG; Todd PS; Siegfried E; Igelman S; Cordoro KM; Tollefson MM
    JAMA Dermatol; 2023 Jun; 159(6):637-642. PubMed ID: 37043214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
    Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of adalimumab in difficult-to-treat psoriasis.
    Lanna C; Zangrilli A; Bavetta M; Campione E; Bianchi L
    Dermatol Ther; 2020 May; 33(3):e13374. PubMed ID: 32246516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Partial reversal of androgenetic alopecia with methotrexate therapy for psoriasis.
    Famenini S; Wu JJ
    Cutis; 2013 Sep; 92(3):127-8. PubMed ID: 24153140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful effect of tocilizumab in anti-TNF-α-induced palmoplantar pustulosis in rheumatoid arthritis.
    Rueda-Gotor J; González-Gay MA; Blanco Alonso R; Gonzalez-Vela C; Lopez-Obregon C; González-López MA
    Joint Bone Spine; 2012 Oct; 79(5):510-3. PubMed ID: 22857979
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review.
    Melo FJ; Magina S
    Int J Dermatol; 2018 Dec; 57(12):1521-1532. PubMed ID: 30028008
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab.
    Andrisani G; Marzo M; Celleno L; Guidi L; Papa A; Gasbarrini A; Armuzzi A
    Eur Rev Med Pharmacol Sci; 2013 Oct; 17(20):2831-6. PubMed ID: 24174369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psoriatic alopecia/alopecia areata-like reactions secondary to anti-tumor necrosis factor-α therapy: a novel cause of noncicatricial alopecia.
    Doyle LA; Sperling LC; Baksh S; Lackey J; Thomas B; Vleugels RA; Qureshi AA; Velazquez EF
    Am J Dermatopathol; 2011 Apr; 33(2):161-6. PubMed ID: 21317611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Palmoplantar pustular psoriasis induced by adalimumab: a case report and literature review.
    Ibis N; Hocaoglu S; Cebicci MA; Sutbeyaz ST; Calis HT
    Immunotherapy; 2015; 7(7):717-20. PubMed ID: 26250408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe Infliximab-Induced Alopecia and Scalp Psoriasis in a Woman with Crohn's Disease: Dramatic Improvement after Drug Discontinuation and Treatment with Adjuvant Systemic and Topical Therapies.
    Udkoff J; Cohen PR
    Dermatol Ther (Heidelb); 2016 Dec; 6(4):689-695. PubMed ID: 27844446
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?
    Joyau C; Veyrac G; Dixneuf V; Jolliet P
    Clin Exp Rheumatol; 2012; 30(5):700-6. PubMed ID: 22935567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alopecia secondary to anti-tumor necrosis factor-alpha therapy.
    Ribeiro LB; Rego JC; Estrada BD; Bastos PR; Piñeiro Maceira JM; Sodré CT
    An Bras Dermatol; 2015; 90(2):232-5. PubMed ID: 25830994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa.
    Tsiogka A; Liakou AI; Agiasofitou E; Gregoriou S; Stratigos A; Rigopoulos D; Kontochristopoulos G
    Dermatology; 2023; 239(6):937-941. PubMed ID: 37579735
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paradoxical psoriasis induced by TNF-α blockade shows immunological features typical of the early phase of psoriasis development.
    Fania L; Morelli M; Scarponi C; Mercurio L; Scopelliti F; Cattani C; Scaglione GL; Tonanzi T; Pilla MA; Pagnanelli G; Mazzanti C; Girolomoni G; Cavani A; Madonna S; Albanesi C
    J Pathol Clin Res; 2020 Jan; 6(1):55-68. PubMed ID: 31577850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Case of psoriasiform and pustular eruptions in addition to alopecia as a paradoxical reaction induced by infliximab.
    Shimokata M; Namiki T; Tokoro S; Ugajin T; Miura K; Yokozeki H
    J Dermatol; 2018 Dec; 45(12):e331-e333. PubMed ID: 29855072
    [No Abstract]   [Full Text] [Related]  

  • 36. Effective treatment with guselkumab for psoriatic alopecia as paradoxical reaction.
    Hosokawa Y; Hamada T; Ashida H; Ikeda M
    J Dermatol; 2019 Aug; 46(8):e302-e303. PubMed ID: 30861165
    [No Abstract]   [Full Text] [Related]  

  • 37. Clinical management of paradoxical psoriasiform reactions during TNF- α therapy.
    Navarro R; Daudén E
    Actas Dermosifiliogr; 2014 Oct; 105(8):752-61. PubMed ID: 23938073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis.
    Leonardi C; Papp K; Strober B; Thaçi D; Warren RB; Tyring S; Arikan D; Karunaratne M; Valdecantos WC
    Br J Dermatol; 2019 Jan; 180(1):76-85. PubMed ID: 30169904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease.
    George LA; Gadani A; Cross RK; Jambaulikar G; Ghazi LJ
    Dig Dis Sci; 2015 Nov; 60(11):3424-30. PubMed ID: 26115749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infliximab and adalimumab-induced psoriasis in Crohn's disease: a paradoxical side effect.
    Iborra M; Beltrán B; Bastida G; Aguas M; Nos P
    J Crohns Colitis; 2011 Apr; 5(2):157-61. PubMed ID: 21453886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.